PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression

NCT06289517 · tracked via the Priya Life Science China tracker

Sponsor

Peking University First Hospital

Phase

Not applicable

Started

2024-05-28

Last updated

2024-12-18

Condition(s) studied

Neoplasms

Investigational drug(s) / intervention(s)

68Ga-Her2-affibody

68Ga-Her2-affibody: 68Ga-Her2-affibody is injected intravenously with a dose of 0.06-0.08 mCi/kg.

Study summary

This project uses HER2 protein as the target group of radiodrugs to explore the diagnostic efficacy, safety and metabolic characteristics of 68Ga-Her2-affibody in the expression status of HER2, aiming to provide a new imaging method for the determination of HER2 status in breast cancer At the same time, it also provides new methods and means for early diagnosis, accurate staging, recurrence judgment, treatment decision-making and prognosis judgment of malignant tumors such as lung cancer, gastrointestinal cancer and bladder cancer, and provides scientific basis for precise treatment of malignant tumors.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: \- patients with confirmed or suspected cancer; Signed written informed consent Exclusion Criteria: \-

Primary outcome measure(s)

The diagnostic efficacy of 68Ga-Her2-affibody PET/CT in the evaluation of breast cancer — 1 year
the standardized Uptake Value (SUV) of lesions on 68Ga-Her2-affibody PET/CT

Trial sites (1)

Facility	City	Region	Status
Peking University First Hospital	Beijing	Beijing Municipality	Recruiting

More Peking University First Hospital trials in China

Optimizing Prostate Biopsy Schemes in Men With Multiple MRI Visible Lesions Recruiting

Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients Recruiting

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 Starting soon

Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery Starting soon

Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery Starting soon

Other trials for the same condition

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Active, not recruiting

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors Active, not recruiting

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Active, not recruiting

Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors Recruiting

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06289517 on ClinicalTrials.gov ↗ ← All trials in China